Roivant Sciences Ltd. (ROIV)
| Market Cap | 27.61B +99.9% |
| Revenue (ttm) | 7.53M -67.6% |
| Net Income | -266.25M |
| EPS | -0.49 |
| Shares Out | 722.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,671,522 |
| Open | 36.62 |
| Previous Close | 36.04 |
| Day's Range | 35.71 - 38.52 |
| 52-Week Range | 19.32 - 42.50 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 50.00 (+30.79%) |
| Earnings Date | Nov 9, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $50.0, which is an increase of 30.79% from the latest price.
News
Roivant Sciences price target raised to $56 from $46 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Roivant Sciences (ROIV) to $56 from $46 and keeps a Buy rating on the shares ahead of the Q3 report.
Roivant Sciences price target raised to $62 from $55 at TD Cowen
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $62 from $55 and keeps a Buy rating on the shares after “spectacular” Phase 3 data for brepocitinib…
Roivant Sciences Transcript: Study result
In two phase III CLARITY trials, brepocitinib delayed treatment failure through 48 weeks and increased steroid-free quiescence versus placebo. Macular edema and vision-related outcomes also improved; an NIU sNDA is planned for H1 2027.
Roivant Sciences Press release: Study result
Roivant Sciences issued a press release on October 21, 2026, disclosing material business information to investors.
Roivant Sciences Slides: Study result
Roivant Sciences has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Nov...
Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences
Citi analyst Samantha Semenkow added an “upside 90-day catalyst watch” on Roivant Sciences (ROIV) while keeping a Buy rating on the shares with a $46 price target The Phase 3…
Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Roivant Sciences (ROIV) to Peer Perform from Outperform with no price target The stock profile is changing, with good catalysts “now more scarce” and a “stretched valuation,”...
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ...
Roivant Sciences price target raised to $41 from $37.50 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after having hosted CEO Matt…
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Roivant Sciences Transcript: Bank of America Global Healthcare Conference
Recent milestones include positive phase II data for mosliciguat and the launch of LISRAYA in dermatomyositis, with more clinical readouts expected soon. Focus is on commercialization, expanding indications, and advancing FcRn programs, especially in autoimmune and orphan diseases like Graves' disease and non-infectious uveitis.
Roivant Sciences initiated with a Buy at Stifel
Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers a “compelling multi-asset story with scarcity value” within the specialty autoimmune and…
Roivant Sciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant clinical and financial progress was highlighted, including FDA approval for brepocitinib, best-in-class data for mosliciguat in PH-ILD, and strong efficacy for IMVT-1402 in RA. Multiple late-stage readouts and launches are expected in the coming year.
Roivant Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting plans for broader indications and rapid phase III enrollment. Brepocitinib's DM launch is progressing steadily, with strong physician enthusiasm and significant market potential. Key pipeline catalysts include NIU and RA data, while the company maintains a flexible, value-focused corporate structure.
Roivant Sciences price target raised to $55 from $50 at TD Cowen
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $55 from $50 and keeps a Buy rating on the shares. The firm updated its model following the…
Roivant Sciences price target raised to $46 from $42 at Guggenheim
Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy rating on the shares, telling investors that Phase 2 PHocus data for…
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $47 from $41 and keeps a Buy rating on the shares. The firm believes mosliciguat’s results strengthen Roivant’s…
Roivant Sciences rises 18.9%
Roivant Sciences (ROIV) is up 18.9%, or $6.60 to $41.53.
Roivant Sciences price target raised to $52 from $42 at Jefferies
Jefferies raised the firm’s price target on Roivant Sciences (ROIV) to $52 from $42 and keeps a Buy rating on the shares after the company reported “strong” data from its…
Roivant Sciences Transcript: Wells Fargo 21st Annual Healthcare Conference
PHocus phase IIb data in PH-ILD showed unprecedented efficacy and safety, prompting rapid phase III enrollment. LISRAYA launched for dermatomyositis with strong uptake and steroid-sparing benefits. The FcRn pipeline advances in multiple autoimmune indications, with key data readouts and regulatory milestones expected over the next 12–18 months.
Roivant Sciences rises 17.6%
Roivant Sciences (ROIV) is up 17.6%, or $6.15 to $41.08.
Roivant Sciences Transcript: Study result
The PHocus study in PH-ILD showed mosliciguat achieved a record 56.3% reduction in PVR, significant improvements in six-minute walk and NT-proBNP, and a favorable safety profile. Benefits were consistent across subgroups, and a phase III trial is underway to confirm these results.